Alkalinization
Analgesics..
Antiandrogens..
Bromhexine
Budesonide
Cannabidiol
Colchicine
Conv. Plasma
Curcumin
Ensovibep
Famotidine
Favipiravir
Fluvoxamine
Hydroxychlor..
Iota-carragee..
Ivermectin
Lactoferrin
Lifestyle..
Melatonin
Metformin
Molnupiravir
Monoclonals..
Nigella Sativa
Nitazoxanide
Nitric Oxide
Paxlovid
Peg.. Lambda
Povidone-Iod..
Quercetin
Remdesivir
Vitamins..
Zinc

Other
Feedback
Home
Home   COVID-19 treatment studies for Remdesivir  COVID-19 treatment studies for Remdesivir  C19 studies: Remdesivir  Remdesivir   Select treatmentSelect treatmentTreatmentsTreatments
Alkalinization Meta Lactoferrin Meta
Melatonin Meta
Bromhexine Meta Metformin Meta
Budesonide Meta Molnupiravir Meta
Cannabidiol Meta
Colchicine Meta Nigella Sativa Meta
Conv. Plasma Meta Nitazoxanide Meta
Curcumin Meta Nitric Oxide Meta
Ensovibep Meta Paxlovid Meta
Famotidine Meta Peg.. Lambda Meta
Favipiravir Meta Povidone-Iod.. Meta
Fluvoxamine Meta Quercetin Meta
Hydroxychlor.. Meta Remdesivir Meta
Iota-carragee.. Meta
Ivermectin Meta Zinc Meta

Other Treatments Global Adoption
All Studies   Meta Analysis   Recent:  
0 0.5 1 1.5 2+ Severe case 7% Improvement Relative Risk c19early.org/s Bavaro et al. Remdesivir for COVID-19 LATE TREATMENT Is late treatment with remdesivir beneficial for COVID-19? Retrospective 331 patients in Italy (July 2021 - March 2022) Lower severe cases with remdesivir (p=0.00099) Bavaro et al., Viruses, doi:10.3390/v15051199 Favors remdesivir Favors control

Efficacy of Remdesivir and Neutralizing Monoclonal Antibodies in Monotherapy or Combination Therapy in Reducing the Risk of Disease Progression in Elderly or Immunocompromised Hosts Hospitalized for COVID-19: A Single Center Retrospective Study

Bavaro et al., Viruses, doi:10.3390/v15051199
Bavaro et al., Efficacy of Remdesivir and Neutralizing Monoclonal Antibodies in Monotherapy or Combination Therapy in.., Viruses, doi:10.3390/v15051199
May 2023   Source   PDF  
  Twitter
  Facebook
Share
  All Studies   Meta
Retrospective 331 hospitalized COVID-19 patients in Italy, showing lower progression with remdesivir. Combination therapy with mAbs was more effective, and improved results were seen for immunocompromised patients.
[Gérard, Wu, Zhou] show significantly increased risk of acute kidney injury with remdesivir.
risk of severe case, 7.0% lower, RR 0.93, p < 0.001, treatment 120, control 211, propensity score weighting.
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Bavaro et al., 19 May 2023, retrospective, Italy, peer-reviewed, median age 75.0, 27 authors, study period 1 July, 2021 - 15 March, 2022.
Contact: davidebavaro@gmail.com (corresponding author).
All Studies   Meta Analysis   Submit Updates or Corrections
This PaperRemdesivirAll
Abstract: viruses Article Efficacy of Remdesivir and Neutralizing Monoclonal Antibodies in Monotherapy or Combination Therapy in Reducing the Risk of Disease Progression in Elderly or Immunocompromised Hosts Hospitalized for COVID-19: A Single Center Retrospective Study Davide Fiore Bavaro 1, * , Lucia Diella 1 , Alessandra Belati 1 , Giuliana Metrangolo 1 , Laura De Santis 1 , Vito Spada 1 , Michele Camporeale 1 , Angelo Dargenio 1 , Gaetano Brindicci 1 , Flavia Balena 1 , Deborah Fiordelisi 1 , Fabio Signorile 1 , Giacomo Loseto 2 , Crescenza Pasciolla 2 , Carla Minoia 2 , Immacolata Attolico 3 , Tommasina Perrone 3 , Simona Simone 4 , Maria Rendina 5 , Nicoletta Giovine 6 , Francesco Di Gennaro 1 , Pellegrino Musto 3,7 , Attilio Guarini 2 , Alfredo Di Leo 5 , Loreto Gesualdo 4 , Maria Dell’Aera 6 and Annalisa Saracino 1 1 2 3 4 Citation: Bavaro, D.F.; Diella, L.; 5 Belati, A.; Metrangolo, G.; De Santis, L.; Spada, V.; Camporeale, M.; 6 Dargenio, A.; Brindicci, G.; Balena, F.; 7 et al. Efficacy of Remdesivir and Neutralizing Monoclonal Antibodies * Clinic of Infectious Diseases, Department of Precision and Regenerative Medicine and Ionian Area, University of Bari, Piazza G. Cesare 11, 70124 Bari, Italy Hematology Unit, IRCCS Istituto Tumori “Giovanni Paolo II”, 70124 Bari, Italy Unit of Hematology and Stem Cell Transplantation, AOUC Policlinic, 70124 Bari, Italy Nephrology Dialysis and Transplantation Unit, Department of Precision and Regenerative Medicine and Ionian Area, University of Bari, 70124 Bari, Italy Section of Gastroenterology, Department of Emergency and Organ Transplantation, University of Bari, 70124 Bari, Italy Hospital Pharmacy Department, University Hospital of Bari, 70124 Bari, Italy Department of Precision and Regenerative Medicine and Ionian Area University of Bari and Unit of Hematology and Stem Cell Transplantation, AOUC Policlinico, 70124 Bari, Italy Correspondence: davidebavaro@gmail.com; Tel.: +39-080-5594529; Fax: +39-080-5592301 in Monotherapy or Combination Therapy in Reducing the Risk of Disease Progression in Elderly or Immunocompromised Hosts Hospitalized for COVID-19: A Single Center Retrospective Study. Viruses 2023, 15, 1199. https://doi.org/ 10.3390/v15051199 Academic Editors: Karolina Akinosoglou, George T. Dimopoulos and Wei Xu Received: 29 April 2023 Revised: 16 May 2023 Accepted: 17 May 2023 Published: 19 May 2023 Copyright: © 2023 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article Abstract: Introduction: Remdesivir (REM) and monoclonal antibodies (mAbs) could alleviate severe COVID-19 in at-risk outpatients. However, data on their use in hospitalized patients, particularly in elderly or immunocompromised hosts, are lacking. Methods: All consecutive patients hospitalized with COVID-19 at our unit from 1 July 2021 to 15 March 2022 were retrospectively enrolled. The primary outcome was the progression to severe COVID-19 (P/F < 200). Descriptive statistics, a Cox univariate–multivariate model, and an inverse probability treatment-weighted (IPTW) analysis were performed. Results: Overall, 331 subjects were included; their median (q1–q3) age was 71 (51–80) years, and they were males in 52% of the cases. Of them, 78 (23%) developed severe COVID-19. All-cause in-hospital mortality was 14%; it was higher in those with disease progression (36% vs. 7%, p < 0.001). REM and mAbs resulted in a 7% (95%CI = 3–11%) and 14% (95%CI = 3–25%) reduction in the risk of severe..
Late treatment
is less effective
Please send us corrections, updates, or comments. Vaccines and treatments are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop   
Submit